ESOMEPRAZOLE SODIUM - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for esomeprazole sodium and what is the scope of freedom to operate?
Esomeprazole sodium
is the generic ingredient in two branded drugs marketed by Accord Hlthcare, Deva Holding As, Eugia Pharma, Gland Pharma Ltd, Mylan, Slate Run Pharma, Sun Pharm, and Astrazeneca, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.There are thirteen drug master file entries for esomeprazole sodium. Five suppliers are listed for this compound.
Summary for ESOMEPRAZOLE SODIUM
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 8 |
NDAs: | 8 |
Drug Master File Entries: | 13 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 180 |
Clinical Trials: | 8 |
Patent Applications: | 5,960 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ESOMEPRAZOLE SODIUM |
What excipients (inactive ingredients) are in ESOMEPRAZOLE SODIUM? | ESOMEPRAZOLE SODIUM excipients list |
DailyMed Link: | ESOMEPRAZOLE SODIUM at DailyMed |
Recent Clinical Trials for ESOMEPRAZOLE SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Livzon Pharmaceutical Group Inc. | Phase 3 |
Food and Drug Administration (FDA) | Phase 1 |
BioPharma Services, Inc | Phase 1 |
Pharmacology for ESOMEPRAZOLE SODIUM
Drug Class | Proton Pump Inhibitor |
Mechanism of Action | Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ESOMEPRAZOLE SODIUM
Paragraph IV (Patent) Challenges for ESOMEPRAZOLE SODIUM
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
NEXIUM IV | For Injection | esomeprazole sodium | 20 mg/vial and 40 mg/vial | 021689 | 1 | 2009-11-23 |
US Patents and Regulatory Information for ESOMEPRAZOLE SODIUM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eugia Pharma | ESOMEPRAZOLE SODIUM | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 204657-002 | Aug 10, 2016 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Astrazeneca | NEXIUM IV | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 021689-002 | Mar 31, 2005 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Gland Pharma Ltd | ESOMEPRAZOLE SODIUM | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 203349-001 | Apr 1, 2020 | RX | No | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Accord Hlthcare | ESOMEPRAZOLE SODIUM | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 205379-001 | Sep 25, 2015 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Mylan | ESOMEPRAZOLE SODIUM | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 202686-001 | May 17, 2017 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Slate Run Pharma | ESOMEPRAZOLE SODIUM | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 215732-001 | Feb 10, 2022 | AP | RX | No | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Astrazeneca | NEXIUM IV | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 021689-001 | Mar 31, 2005 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ESOMEPRAZOLE SODIUM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astrazeneca | NEXIUM IV | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 021689-001 | Mar 31, 2005 | 5,877,192*PED | ⤷ Subscribe |
Astrazeneca | NEXIUM IV | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 021689-002 | Mar 31, 2005 | 6,143,771 | ⤷ Subscribe |
Astrazeneca | NEXIUM IV | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 021689-002 | Mar 31, 2005 | 5,877,192*PED | ⤷ Subscribe |
Astrazeneca | NEXIUM IV | esomeprazole sodium | INJECTABLE;INTRAVENOUS | 021689-001 | Mar 31, 2005 | 6,143,771 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
ESOMEPRAZOLE SODIUM Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.